%0 Journal Article
%T Original research article: High incidence of atrial fibrillation in patients treated with ibrutinib
%A Ariel Cohen
%A Charles Dolladille
%A Chlo¨Ś Ammar
%A Florian Baptiste
%A Franck Paganelli
%A Franck Thuny
%A Jennifer Cautela
%A Jeremie Barraud
%A Joachim Alexandre
%A Laure Farnault
%A Marion Escudier
%A Michael Peyrol
%A M¨Ślanie Gaubert
%A No¨Śmie Resseguier
%A Stephane Ederhy
%A Th¨Śr¨¨se Aurran
%A Yan Ancedy
%J Archive of "Open Heart".
%D 2019
%R 10.1136/openhrt-2019-001049
%X Atrial fibrillation (AF) is one of the most common side effects of ibrutinib, a drug that has dramatically improved the prognosis of chronic B-cell malignancies such as chronic lymphocytic leukaemia (CLL). The true incidence of ibrutinib-related AF (IRAF) is not well known and its therapeutic management poses unique challenges especially due to the inherent risk of bleeding. We aimed to determine the incidence and predictors of IRAF, and to analyse its management and outcome
%K atrial fibrillation
%K cardio-oncology
%K cardiotoxicity
%K ibrutinib
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519413/